Grant: Discovery Grants Program - Individual
Simon Fraser University
$35,000.00
Understanding the driver mutations of canine lymphoma: towards new biomarkers and repositioning human therapies
EF 2016-17
Résumé
Cancer is the number one cause of premature death in dogs and lymphoma is the most common of the canine cancers. Compared to our current knowledge of the genetic changes that occur in human oncogenesis we know little about the mutations that arise in the development of canine cancers including lymphoma. Over the past decade a new generation generation of cancer drugs for treating human cancers have been rationally developed based on the genetic makeup of tumours. An improved understanding of canine lymphoma may allow such ""targeted"" cancer therapies, originally developed for application to human cancers, to also be ""repositioned"" for application to veterinary cancers. Using new DNA sequencing technologies, I will search the DNA from canine cancers, beginning with lymphomas, for genetic changes (mutations) that are responsible for converting normal cells to lymphoma cancer cells. Focus will be placed on the genes with shared functions (orthologues) to human lymphoma-related genes. I will also search for dosage changes (""gene expression"") likely to be associated with the cancer phenotype. Such analyses can reveal new disease subtypes and prognostic biomarkers that allow us to better predict which animals tumours will respond well to current treatment regimens. Analyzing these types of data requires sophisticated computational approaches collectively referred to as ""bioinformatics"". New bioinformatics techniques will be developed here to facilitate the analysis of tumour DNA sequence from dogs. I will also develop new molecular approaches to non-invasively search in bodily fluids for the somatic mutations identified in this study. For example, assays will be developed to detect the tumour-specific mutations in the blood plasma of dogs for use as ""biomarkers"". This work may eventually allow us to diagnose lymphomas more accurately and with less invasive tests than those currently being used. The methods used here can ultimately be generalized to veterinary cancers in both dogs and cats.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
435398-2013
Name nom
Morin, Ryan
Department département
Molecular Biology and Biochemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2013
Award amount
35000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
505
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Veterinary pharmaceuticals
Area of application fr
Produits pharmaceutiques à usage vétérinaire
Research subject code
5300
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Molecular biology
Research subject fr
Biologie moléculaire
Partie
4
Nb partie
5
Application title
Understanding the driver mutations of canine lymphoma: towards new biomarkers and repositioning human therapies
Keyword
NSERC
Application summary
Cancer is the number one cause of premature death in dogs and lymphoma is the most common of the canine cancers. Compared to our current knowledge of the genetic changes that occur in human oncogenesis we know little about the mutations that arise in the development of canine cancers including lymphoma. Over the past decade a new generation generation of cancer drugs for treating human cancers have been rationally developed based on the genetic makeup of tumours. An improved understanding of canine lymphoma may allow such ""targeted"" cancer therapies, originally developed for application to human cancers, to also be ""repositioned"" for application to veterinary cancers. Using new DNA sequencing technologies, I will search the DNA from canine cancers, beginning with lymphomas, for genetic changes (mutations) that are responsible for converting normal cells to lymphoma cancer cells. Focus will be placed on the genes with shared functions (orthologues) to human lymphoma-related genes. I will also search for dosage changes (""gene expression"") likely to be associated with the cancer phenotype. Such analyses can reveal new disease subtypes and prognostic biomarkers that allow us to better predict which animals tumours will respond well to current treatment regimens. Analyzing these types of data requires sophisticated computational approaches collectively referred to as ""bioinformatics"". New bioinformatics techniques will be developed here to facilitate the analysis of tumour DNA sequence from dogs. I will also develop new molecular approaches to non-invasively search in bodily fluids for the somatic mutations identified in this study. For example, assays will be developed to detect the tumour-specific mutations in the blood plasma of dogs for use as ""biomarkers"". This work may eventually allow us to diagnose lymphomas more accurately and with less invasive tests than those currently being used. The methods used here can ultimately be generalized to veterinary cancers in both dogs and cats.